Computational Pathology blog

Propelling Pharma on the Computational Pathology Revolution

By Sylvain Berlemont, PhD, Founder and CEO - 08 Nov 2021

In this interview, Sylvain Berlemont, founder and CEO of Keen Eye, shares his vision on Computational Pathology.

 

Keen Eye’s SaaS-based Computational Pathology platform has been playing a phenomenal role in Digital Pathology by offering pharmaceutical companies the much-needed agility and efficacy in operations while staying compliant with the regulations. Be it optimising translational research, enhancing CDx/IVD assay development, or accelerating clinical trials, Keen Eye’s platform is built from the ground up, considering every touchpoint in the research process. 

 

Keen Eye is deploying a unique combination of a powerful AI-technology, a smart cloud-based platform and a mature approach to regulatory compliance.

 

Access the full interview below:

Keen Eye has at heart to simplify the adoption of Computational Pathology to guide pharmaceutical companies in better diagnostics and drug development. 

Find out how Keen Eye can be your driving force for success